- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03336788
Virtual Reality Combined With rTMS for the Treatment of Depression : a Randomized Clinical Trial. (TMS VR)
Depression is a mood disorder affecting an individual in its entirety, altering its emotional and intellectual functioning . The major form of depression is the most common psychiatric disorder in Western countries. It is considered to be the most expensive psychiatric neurological disease in Europe and is currently treated by different methods.
However, almost a third of depressed patients shows no clinical improvement. Advances in neuroscience and understanding of neuromodulation have enabled the emergence of new treatments such as the repetitive transcranial magnetic stimulation (rTMS) . It consists of modulating the neuronal activity of a targeted brain region through a magnetic field applied by a coil. Even though this form of treatment has proven to be effective, it appears that more than half of depressed patients exhibited little to no response to it.
As brain regions targeted by TMS may also be stimulated beforehand by sensory afferent signals, it was hypothesized that optimizing the effects of TMS with virtual reality is possible through the activation of these brain regions with sensory stimuli holding emotional valence (images, sounds) while using TMS concomitantly. Based on this new research premise, the investigators propose, in the context of an open and controlled clinical trial, to use a new media entitled virtual reality for displaying interactive virtual environments with positive emotional valence ( field of flowers, green valley) to a group of depressed patients undergoing TMS at the same time.
The study will include 66 depressed patients randomly assigned into two groups : TMS and Virtual Reality Versus TMS alone. Any differences in therapeutic efficacy between the two groups will be measured by questionnaires and brain functional imagery. This innovative and therapeutic approach will allow us to better understand the appropriate processes for modulating the neuronal activity in specific brain areas for treatment purposes.
연구 개요
상태
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Marseille, 프랑스, 13354
- 모병
- Assistance Publique Hopitaux de Marseille
-
연락하다:
- Raphaëlle RICHIERI, PH
- 전화번호: +33 491435551
- 이메일: raphaellemarie.richieri@ap-hm.fr
-
수석 연구원:
- Raphaëlle RICHIERI, PH
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Criteria of resistant depression
- Age from 18 to 65 years old included.
- Primary diagnosis of major depression in subjects according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria.
- Informed consent and signed to participate in the study
Exclusion Criteria:
- Pregnant woman, parturient and nursing mothers.
- Absence of DSM-5 criteria for depression in subjects.
- Refusal to participate in the study.
- Modification of drug treatment in the month preceding inclusion.
- History of neurological pathology, head trauma or mental retardation.
- Presence of an addictive comorbidity.
- Presence of a major organic pathological.
- Presence of a contra-indication to virtual reality
- Presence of intracerebral ferro-metallic material, cochlear implant, pacemaker
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: TMS
|
20 sessions navigated with Conventional Transcranial Magnetic Stimulation
|
|
활성 비교기: TMS with virtual reali
|
20 sessions navigated with Conventional Transcranial Magnetic Stimulation
20 sessions navigated with virtual reality
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Evaluation of the depression score in Montgomery-asberg Depression Rating Scale (MADRS).
기간: 36 months
|
a heteroevaluation scale of depressive semiology in 10 items.
A decrease of at least 50% in initial score at the Montgomery-asberg Depression Rating Scale.
|
36 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Evaluation of The State Trait Anxiety Inventory Self-Questionnaire
기간: 36 months
|
40 items with, for each, 4 modalities of response, corresponding to degrees of intensity or frequency of the habitual or general emotional state of the patient.
The calculated score varies between 20 and 80, a high score indicating the presence of anxiety.
Anxiety will be assessed before the program begins and at the end of the program.
|
36 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Raphaëlle RICHIERI, PH, Assistance Publique Hopitaux de Marseille
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
the Treatment of Depression에 대한 임상 시험
-
University Hospital Inselspital, BerneDeka Medical, Inc.모집하지 않고 적극적으로
-
Catherine Vandepitte, M.D.Pacira Pharmaceuticals, Inc완전한
Transcranial Magnetic Stimulation (TMS - ) MagPro®에 대한 임상 시험
-
Hospital Center Guillaume Régnier모병
-
The Mind Research NetworkUniversity of New Mexico모집하지 않고 적극적으로
-
Assistance Publique Hopitaux De Marseille완전한